Efficacy and safety of anlotinib maintenance therapy in limited-stage small cell lung cancer.

Discov Oncol · 2025 · PMC12595152 · PMID 41201522

Europe PMC DOI

hedged sentence

0.1400

closest p · 2.8× alpha

0.1400

boldest claim

The sentences

did not reach statistical significanceP = 0.140not close (p > 0.1)

Although the ORR in the anlotinib group was more than twice that of the control group numerically, the difference did not reach statistical significance (χ2 = 3.982, P = 0.140).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.